Moberg Pharma lowers expectations on main endpoint in ongoing section 3 trial following information in a subset of sufferers By Investing.com
STOCKHOLM, Sept. 13, 2024 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) broadcasts…
By
Tycoon Herald
8 Min Read